MyFinsight
Home
Blog
About
Proceeds from notes
payable, net of original...
$5,970,000
(2288.00%↑ Y/Y)
Redemption of short term
investments
-$1,500,000
Proceeds from
subscription receivable on...
$1,002
Net cash provided by
financing activities
$3,466,002
(-71.42%↓ Y/Y)
Net cash provided by
(used in) investing...
$1,500,000
(11319.99%↑ Y/Y)
Canceled cashflow
$2,505,000
Net change in cash
and cash...
-$701,163
(-108.03%↓ Y/Y)
Canceled cashflow
$4,966,002
Unrealized gain from
changes in fair value of...
-$13,196,057
Accretion on convertible
notes
$1,859,744
Non-cash interest
$1,212,398
Prepaid expenses and
other current assets
-$296,013
(-116.55%↓ Y/Y)
Proceeds from sales of
digital assets, net of...
$177,901
Accounts payable and
accrued expenses
$168,453
(135.69%↑ Y/Y)
Stock based
compensation - option grants
$105,210
(-93.81%↓ Y/Y)
Depreciation and
amortization expense
$40,324
Repayment of notes payable
$1,000,000
something is missing
-$995,000
Payment of debt issuance
costs
$510,000
Net cash used in
operating activities
-$5,667,166
(-67.60%↓ Y/Y)
Canceled cashflow
$17,056,100
Net loss
-$20,173,130
(-558.27%↓ Y/Y)
Realized gain and trading
gains on digital...
$2,004,495
Digital assets received
as yield income
$282,732
Change in fair value of
derivative liability
$215,993
Operating lease liability
-$9,758
Back
Back
Cash Flow
Apimeds Pharmaceuticals US, Inc. (APUS)
Apimeds Pharmaceuticals US, Inc. (APUS)
source: myfinsight.com